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Abstract : Knowing recent drug-resistant bacteria trends is important for proper 
antibacterial drug use to improve the prognosis of patients with infectious diseases 
and for public health.  Because multiple quinolone antibacterial agents are simul-
taneously adopted in hospitals in Japan, we examined whether minimum inhibitory 
concentrations （MICs） against Haemophilus influenzae differ among quinolones.  
We determined MICs of six different quinolone antibacterial agents and performed 
molecular genetic analysis.  We investigated β-lactamase-producing and β-lactamase-
negative ampicillin-resistant（BLNAR）H. inuenzae using the nitrocen method in 
parallel.  Overall, 144 clinical H. inuenzae strains isolated at the Showa University 
Hospital between 2012 and 2017 were subjected to MIC determination for penicil-
lin/quinolone antibacterial agents using the Clinical and Laboratory Standards 
Institute broth microdilution method.  Amino acid mutations in the quinolone resis-
tance-determining regions were analyzed in the isolates showing an MIC value ≥ 
0.25 µg/ml of quinolone antibacterial agents.  BLNAR isolates increased from 2016 
onward.  Among quinolone antibacterial agents, all isolates remained susceptible 
to sitaoxacin.  However, for moxioxacin（MFLX）, strains with an MIC value＝
0.5 µg/ml were detected every year since 2013 except in 2015.  Amino acid muta-
tions were investigated in 17 isolates （11.8％） with MFLX MIC value ≥ 0.25 µg/ml 
and conrmed in 11 isolates （7.6％）, of which 9 contained GyrA mutations.  The 
results demonstrated that MFLX was useful for predicting the presence of amino 
acid mutations and 0.25 was an appropriate MIC threshold for this purpose.  This 
screening procedure may be effective for reducing the inappropriate use of quino-
lones and controlling the emergence of drug-resistant H. inuenzae.
Key words : quinolone resistance, minimum inhibitory concentrations, moxifloxacin, 
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Introduction
　Haemophilus influenzae is the second most common causative bacterium of community-
acquired pneumonia, following Streptococcus pneumoniae, and has taken the leading position after 
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pneumococcal vaccines became popular1）.  β-lactam antibiotics have previously been used for 
the treatment of community-acquired pneumonia.  In the 2000s, however, β-lactamase-producing 
ampicillin-resistant bacteria have increasingly been detected in Canada2）, Japan, and some other 
countries.  Moreover, β-lactamase-negative ampicillin-resistant （BLNAR） bacteria have increas-
ingly been detected in Japan recently3）.
　Meanwhile, uoroquinolones are clinically effective against these bacteria4）, and in particular, 
have frequently been prescribed to outpatients with respiratory and otolaryngologic infections. 
Accordingly, reports on quinolone-resistant H. influenzae have started emerging in the begin-
ning of 2000.  In Spain, low-sensitive strains to ciprooxacin （CPFX） accounted for 43％ of H. 
inuenzae strains in 20075）.  In Taiwan, the levooxacin （LVFX） resistance rate has reportedly 
increased from 2.0％ in 2004 to 24.3％ in 20106）.  These data illustrate that the prevalence of 
quinolone resistance among H. inuenzae isolates is highly variable depending on when the test 
is conducted even within the same country or within the same institution.  Furthermore, high-
level BLNAR strains have been reported to exhibit reduced sensitivity toward uoroquinolones7）.
　Fluoroquinolone resistance is primarily induced through mutations in quinolone resistance-
determining regions （QRDRs） of GyrA gene encoding DNA gyrase or ParC gene encoding 
topoisomerase IV, which cause three-dimensional structural alterations in the respective enzymes 
and decreased the afnity between uoroquinolones and these replication enzymes8）.  In the case 
of H. inuenzae, drug resistance has been shown to be strongly related to serine and aspartic 
acid mutations at positions 84 and 88 of GyrA and of serine at position 84 of ParC9）.  How-
ever, only a few previous studies have investigated mutations in QRDRs in the same institution 
over time and have compared MICs among different quinolones.  In this study, we tested sensi-
tivity levels to quinolone and penicillin antibacterial agents over 6 years in H. inuenzae strains 
that were isolated at the same institution without effects from clinical departments, diseases, or 
specimens, and analyzed genetic mutations in QRDRs in strains with MIC value of ≥ 0.25 µg/
ml of quinolones.  Next, we assessed whether antibacterial efficacies varied among quinolone 
antibacterial agents or whether the bacteria tended to be resistant.
Materials and Methods
Bacterial strains
　We used a total of 144 H. inuenzae strains that were clinically isolated at the Showa Univer-
sity Hospital between 2012 and 2017 and stored in our laboratory.  These H. inuenzae isolates 
were obtained from 90 men and 54 women （age, 0-99 years ; median, 43 years）, including 52 
patients from the department of pediatrics, 35 from the department of respiratory medicine, 14 
from the department of emergency medicine, and 4 from the department of otolaryngology.  H. 
inuenzae strains were isolated from respiratory（n＝130）, otolaryngologic（n＝6）, blood（n＝3）, 
pus（n＝3）, and other（n＝2） samples.
β-Lactamase-producing ability test
　Each bacterial strain was cultured on chocolate agar medium （Nippon Becton-Dickinson, 
83Quinolone Resistance and H. influenzae Mutations
Tokyo, Japan） at 35℃ in 5％ CO2 for 22 hours8）.  Next, drops of nitrocefin （Kantokagaku, 
Tokyo, Japan） were added to H. inuenzae.  The strain was considered capable of producing β- 
lactamase when a red color developed10）.
Drug susceptibility assay
　Susceptibility to antibacterial agents was measured the Clinical and Laboratory Standards Insti-
tute broth microdilution method using 96-well plates11）.  As a basal medium, liquid Haemophilus 
Test Medium （HTM） medium （Eiken, Tokyo, Japan） was added to each well and was supple-
mented with Hematin （15 µg/ml） and NAD （15 µg/ml） （Eiken Chemical, Class Ⅰ bacteria test 
series, frozen plates）.  Each strain was cultured on a chocolate agar medium at 35℃ in 5％ CO2 
for 22 hours, and then a bacterial suspension was prepared at a concentration adjusted to be 
similar to that of McFarland standard （bioMèrieux）, 0.5 using physiological saline.  Finally, each 
well was inoculated with a bacterial suspension （5×105 CFU/ml）.  The plate was incubated at 
35℃ in 5％ CO2 for 22 hours, and MIC values of test drugs for these bacteria were measured.  
　The following test drugs were used: aminobenzylpenicillin （ABPC）, sulbactam/ampicillin （SBT/
ABPC）, clavulanic acid/amoxicillin （CVA/AMPC）, levooxacin （LVFX）, ciprooxacin （CPFX）, 
garenoxacin （GRNX）, moxifloxacin （MFLX）, tosufloxacin （TFLX）, and sitafloxacin （STFX）. 
We determined the MICs of these drugs and calculated a mean value for each of six quinolone 
antibacterial agents.  Finally, we intercompared between the six agents.
Analysis of QRDR amino acid sequences
　H. inuenzae strains showing a MFLX MIC value of ≥ 0.25 µg/ml in the drug susceptibility 
assay were selected as test strains and allowed to grow, as previously described by Shoji et al12）. 
Genomic DNA was extracted using Sepa-Gene （EIDIA Co., Ltd., Tokyo, Japan） from the bacte-
rial cells of the test strains and were allowed to aggregate by adding 99.5％ alcohol, centrifuged 
at 8,000×g to precipitate, and washed with 70％ alcohol.  Using the resulting DNA sample as a 
template, genes encoding QRDRs were amplied by PCR.  For amplication, a mixture solution 
of Taq polymerase （Roche, Mannheim, Germany） and primer13） was used in a T100 thermocy-
cler （BIORAD, CA, USA） under PCR conditions as previously described by Shoji et al12）.  
　For purification/separation and extraction, the entire PCR product was subjected to elec-
trophoresis in 2％ agarose gel （TAKARA, Shiga, Japan） under 120 V/h for 1 hour in Tris-
borate-EDTA （NIPPON GENE, Tokyo, Japan） buffer.  The gel was then stained with ethidium 
bromide to detect the target PCR product bands （GyrA : 375bp, ParC : 370bp）, and the detected 
bands were excised.  Thereafter, DNA was extracted and puried from the excised gel segments 
using a GenElute Minus EtBr Spin Column （SIGMA-ALDRICH, St, Louis, USA） and concen-
trated with ethanol.  For direct sequencing using the resulting DNA samples as templates, PCR 
amplication was performed using Big Dye Terminator v1.1 cycle sequencing kit （Applied Bio-
systems Japan, Tokyo, Japan）.  The PCR primers described above were used here as sequence 
primers.  
　The resulting sequencing solutions were analyzed using an ABI PRISM 310 genetic analyzer 
Yasuhiro NAGATOMO, et al84
（Applied Biosystems, Foster City, CA）, and nucleotide sequences of the target gene regions 
were determined.  Based on the nucleotide sequence data obtained, amino acid sequences were 
analyzed using GENETYX Ver.8（GENETYX, Tokyo, Japan） to locate amino acid mutations in 
QRDRs.
Statistical analysis
　Statistical analysis was performed with SPSS statistics version 23.0 （IBM Japan, Tokyo, Japan）. 
Tukey’s honestly signicant difference post-hoc test was used to compare the susceptibilities of 
isolated strain toward quinolones.  All statistical tests were two-tailed, and a P-value of ＜ 0.05 
was considered signicant.
Ethics
　This study was approved by the research ethics committee of Showa University School of 
Health Sciences （Approval No.371）.
Results
BLNAR and β-lactamase-producing bacteria
　Percentages of BLNAR and β-lactamase-producing bacteria over time are shown in Figure 1. 
Among all tested strains, BLNAR strains accounted for 38.9％ in 2012, 22.2％ in 2013, 37.0％ in 
2014, 15.0％ in 2015, 43.5％ in 2016, and 63.6％ in 2017, and the percentage of BLNAR strains 
consecutively increased in 2016 and 2017.  In 2017, aminobenzylpenicillin （ABPC）-resistant 
strains, including β-lactamase-producing ones, accounted for 78.8％ of all isolates.  β-Lactamase-
producing amoxicillin/clavulanic acid-resistant H. inuenzae was not detected.
Fig. 1.  Percentage of BLNAR and β-lactamase-positive Haemophilus influenzae 
isolates in different years : Percentages of BLNAR isolates increased to be 
15.0％ in 2015, 43.5％ in 2016, and 63.6％ in 2017. β-lactamase-producing 
isolates accounted for 15.2％ in 2017.
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Susceptibility to quinolones
　MIC values of various quinolone antibacterial agents measured with 144 H. inuenzae isolates 
are shown （Figure 2）.  For all quinolones, non-susceptible strains as dened with MIC value of ≥
2 µg/ml were found.  For STFX in particular, no strains showing MIC values of ≥ 0.12 µg/ml were 
detected during the study period.  For MFLX, only 80％ of strains had an MIC value of ≤ 0.06.
Comparison of susceptibility to MFLX and other quinolones 
　A cross-comparison of MIC mean values of six quinolone antibacterial agents against 144 
experimental strains indicated that MFLX had signicantly higher MIC mean value than STFX 
and TFLX（p＝0 and 0.02, respectively） （Table 1）.  For MFLX, one or more isolates with MIC 
values of ≥ 0.5 µg/ml were detected every year since 2013 except in 2015 （Table 2）.  This series 
of results demonstrated that the antibacterial potency of MFLX was lower than that of any 
other antibacterial agent tested.  
Fig. 2.  Cumulative MIC values of fluoroquinolones for Haemophilus influenzae isolates
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Table 1.  MIC values of quinolones against Haemophilus inuenzae and cross-comparison
P value
 
MIC50 MIC90
vs.
CPFX
vs.
GRNX
vs.
LVFX
vs.
MFLX
vs.
STFX
vs.
TFLX
CPFX 0.03 0.03 ― 1.000 1.000 0.176 0.134 0.966
GRNX 0.03 0.06 ― 1.000 0.091 0.245 0.955
LVFX 0.03 0.06 ― 0.086 0.256 0.996
MFLX 0.06 0.25 ― 0.000＊ 0.020＊
STFX 0.03 0.03 ― 0.558
TFLX 0.03 0.06 ―
＊MFLX had signicantly higher MIC average value than STFX and TFLX.
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Amino acid mutations in QRDRs of GyrA and ParC
　We investigated amino acid mutations in QRDRs of GyrA and ParC in 17 strains with low 
susceptibility to MFLX（MIC ≥ 0.25 µg/ml）.  Mutations were found in 11 strains and detected 
every year except in 2015（Table 2）.  Of all H. inuenzae strains isolated in each year, strains 
with any amino acid mutation accounted for 11.1％ in 2012, 5.6％ in 2013, 14.8％ in 2014, 8.3％ 
in 2016, and 5.3％ in 2017（total 7.6％ in the past six years）.  Only one mutation was found in 
GyrA（Ser84Leu） in eight strains or in ParC（Ser84Ile or Gly82Arg）in two strains, and one 
mutation each in GyrA（Ser84Leu） and ParC（Ser84Ile）.  Both strains with the Ser84Ile mutation 
（2017-1 and 2017-2） had MFLX MIC ≥ 0.5 µg/ml, CPFX MIC＝1 µg/ml, GRNX MIC ≥ 0.25 µg/
ml, LVFX MIC＝0.5 µg/ml, and TFLX MIC＝1 µg/ml, which indicated reduced susceptibility.
BLNAR and amino acid mutations in QRDRs
　Of the 11 isolates with any amino acid mutation, 5 （2012-2, 2014-1, 2014-3, 2017-1, and 2017-2）
were BLNAR, and all but 2012-2 exhibited reduced susceptibility to uoroquinolones except for 
STFX （Table 2）.
Discussion
 In Japan, no Hib strains have been detected in children with invasive infections after Hib 
vaccines were introduced in 200814）.  However, the frequency of isolation of BLNAR strains is 
Table 2.   Association between low quinolone susceptibility and QRDR mutations in strains 
isolated at the Showa University Hospital
Strain Mutation
MFLX CPFX GRNX LVFX TFLX STFX GyrA ParC
2012-1 1 0.25 1 0.25 0.25 0.06 Ser84Leu   -
2012-2 0.25 0.03 0.12 0.06 0.03 0.03 - Gly82Arg
2013-1 0.5 0.25 0.5 0.25 0.25 0.03 Ser84Leu   -
2014-1 0.5 0.25 0.5 0.25 0.25 0.03 Ser84Leu   -
2014-2 0.5 0.25 0.5 0.12 0.12 0.03 Ser84Leu   -
2014-3 0.5 0.25 0.25 0.25 0.12 0.03 Ser84Leu   -
2014-4 0.25 0.12 0.25 0.12 0.06 0.03 Ser84Leu   -
2014-5 0.5 0.5 0.12 0.5 0.12 0.03    -   -
2014-6 0.25 0.03 0.06 0.06 0.06 0.03    -   -
2014-7 0.25 0.03 0.06 0.03 0.06 0.03    -   -
2015-1 0.25 0.5 0.06 0.5 0.12 0.03    -   -
2016-1 0.5 0.5 0.25 1 0.12 0.03 Ser84Leu   -
2016-2 0.5 0.5 0.12 0.5 0.12 0.03 Ser84Leu   -
2016-3 0.25 0.03 0.06 0.03 0.03 0.03    -   -
2017-1 1 1 0.5 0.5 1 0.06    - Ser84Ile
2017-2 0.5 1 0.25 0.5 1 0.03 Ser84Leu Ser84Ile
2017-3 0.5 0.03 0.12 0.03 0.03 0.03    -   -
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high in some areas : 35.8％ in the otorhinolaryngology area in 20123）, and 36.4％ in the pediatric 
area in 201515）; a rate of 36.9％ has also been reported for 2016 surveillance isolates in Japan16）. 
Additionally, the present study showed that the frequency of isolation of BLNAR strains 
increased to 63.6％ in 2017 （Figure 1）.  Possible factors contributing to the observed increase 
in BLNAR include the inappropriate oral cephem use17） and transmission from children to their 
parents.
　Fluoroquinolone resistance rates of H. inuenzae previously studied in Japan were extremely 
low, and the 2016 respiratory specimen surveillance isolates report also stated that the resistance 
to CPFX and LVFX was found in 0.6％ and STFX resistance was found in 0％ of isolates16）. 
STFX is characterized by the strong inhibitory potencies against both DNA gyrase and topoi-
somerase IV18）.  The well-preserved STFX sensitivity owing to this characteristic was consistent 
with that reported in other reports7, 12） and the present ndings.
　Meanwhile, the MFLX resistance rate in H. inuenzae isolates is reportedly 1.1％ in 201019）; 
however, it is noteworthy that low susceptibility to MFLX was observed for 11.8％ （17 of 144） 
of isolates collected from 2012 to 2017 in the present study, possibly attributable to the fact 
that MFLX can be orally administered in Japan, whereas injectable formulations are available 
in Europe and the United States.  Interestingly, the mutant prevention concentration （MPC） of 
uoroquinolone for H. inuenzae is 0.125-0.25 µg/ml for MFLX20）; this MPC differs substantially 
from those of LVFX （0.024-0.391 µg/ml）, GRNX （0.024-0.391 µg/ml）, and STFX （0.003-0.049 µg/
ml）21）.  Thus, it is plausible that if certain drugs such as antacids and laxatives are taken, the 
MFLX level in blood does not adequately increase, and MFLX resistance is acquired if the 
blood MFLX level remains below MPC for a long period of time.  The drug resistance epidemic 
status in the working area should be understood in this regard as well.  
　Additionally, MIC values of LVFX and GRNX, which are frequently used in Japan, and MIC 
value of CPFX, which is often used against Pseudomonas aeruginosa, also tended to be elevated. 
In 2017, two isolates with TFLX MIC＝1 µg/ml （one from a child） were identied.  After the 
recent approval for treatment of respiratory infections in children as an additional indication in 
Japan, opportunities of prescribing TFLX are increasing, and there is a concern that this led to 
an increase in the prevalence of TFLX resistance22）.
　Considering that MIC value of MFLX is relatively higher than the MIC values of other qui-
nolones （Table 1） and two of six isolates with MFLX MIC value of 0.25 µg/ml had amino acid 
mutations in QRDRs （Table 2）, MIC values of MFLX appear to be more useful than those of 
other quinolones as a reference to nd bacterial isolates with reduced susceptibility to quinolone 
antibacterial agents.  Therefore, we believe that MFLX is suited for MIC assays to screen bacte-
rial isolates with uoroquinolone resistance, particularly in Japan.  Furthermore, considering the 
reports by Shoji12） and Perez5）, we propose that an MFLX MIC value of 0.25 µg/ml is an appro-
priate threshold to screen bacterial isolates for amino acid mutations in QRDRs.
　While QRDR mutations in H. inuenzae occur in GyrA, GyrB, ParC, ParE, and some other 
proteins, QRDR mutations are found more frequently at Ser84 and Asp88 of GyrA gene and 
at Ser84, Glu88, and Gly82 of ParC gene than at other positions7, 12）.  In addition, the rst and 
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second step mutations have been reported to occur in GyrA and ParC, respectively23）.  Accord-
ingly, we also focused on GyrA and ParC in the present study.  In the case of H. inuenzae, 
previous studies have demonstrated that MICs increase when strains have mutations at Ser84 in 
GyrA QRDRs or at Gly82 or Ser84 in ParC QRDRs6, 12）.  In this study, we analyzed 17 isolates 
showing MFLX MIC value of ≥ 0.25 µg/ml and found that nine isolates had a leucine mutation 
at Ser84 of GyrA gene （Table 2）, a nding that is consistent with previous reports.  Considering 
the reports on Escherichia coli, Klebsiella pneumoniae24） and other bacteria, this finding sug-
gests that GyrA is a likely primary target of quinolones for their antimicrobial activity similarly, 
against H. inuenzae.
　In this study, 2012-2 and 2017-1 isolates were found to have mutations only in ParC （Table 2）. 
Related to this result, Shoji et al obtained a mutant with the mutation only at Ser84 of ParC 
gene among hot spots in a resistance induction experiment12）.  The MFLX MIC for this mutant 
was 0.5 µg/ml, indicating low susceptibility.  This induction experiment showed that Ser84 is an 
important mutation site for H. inuenzae to acquire quinolone resistance, supporting the nding 
in the clinical isolates in the present study.  
　While MIC values have been reported to increase as the number of QRDR mutations 
increases12, 25）, only one isolate was found to have two mutations in the present study.  The 
isolate 2017-2 showed reduced susceptibility to all uoroquinolones except for STFX, a nding 
supporting the above MIC changes （Table 2）.  
　Isolate 2014-5 showed a high MIC value （0.5 µg/ml） for not only MFLX but also CPFX and 
LVFX, although this isolate had no mutations in QRDRs of both GyrA and ParC enzymes 
（Table 2）.  A factor presumably involved in this is a drug efflux pump （acrAB）25） or H. 
inuenzae-specic porin26）, the protein structure of which is similar to that of porin （OmpF）. 
Solid evidence was not obtained from the present study, and this point remains to be addressed 
in future studies.
　It is difficult to predict whether the frequency of quinolone-resistant H. influenzae isolates 
will increase in the future.  Nevertheless, we consider that an outbreak of quinolone-resistant H. 
inuenzae is likely to occur in Japan because the population aged ＞ 65 years is a risk factor for 
this resistance6）, quinolone-resistant E. coli is increasing rapidly over recent years, and quinolone-
resistant E. coli isolates have mutations in DNA gyrase and topoisomerase IV24）.  In 2015, a 
global action plan on antimicrobial resistance （AMR） was adopted by the World Health Assem-
bly, and member countries developed national action plans.  In Japan, a milestone is to halve 
the amount of use of broad-spectrum oral antibacterial agents, including oral uoroquinolones by 
2020.  Therefore, monitoring the trend of occurrence of uoroquinolone-resistant H. inuenzae 
isolates is likely to have a substantial meaning to AMR countermeasures.
　In clinical practice, the presence of a drug resistance gene does not necessarily indicate that 
the isolate has a reduced susceptibility to that antibacterial agent （i.e., silence mutations）27）. 
However, acquisition of quinolone resistance is facilitated by quinolone use.  Therefore, the emer-
gence of quinolone-resistant bacteria can be prevented and future medical care against infectious 
diseases wound benet if we can eliminate the unnecessary antibacterial drug use by promoting 
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proper antibacterial drug use.  To achieve this and thereby improve the prospects of future 
medical treatments against infectious diseases, we should preset MFLX in the commercial drug 
sensitivity panel.
　Limitations of this study include that we could not follow clinical courses of cases in which 
isolates with low quinolones susceptibility were found and that we could not determine the 
resistance status in other institutions.  Close monitoring of changes in drug resistance and clinical 
characteristics should be jointly performed at multiple sites.
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